Prometrium in Adolescents Ages 12 to 17: Transitioning to Adult Care

Why Adolescents Use Prometrium

Prometrium delivers progesterone in its bioidentical, micronized form, which the body metabolizes similarly to endogenous progesterone. Several distinct clinical situations bring adolescents to this therapy.

Secondary Amenorrhea and Abnormal Uterine Bleeding

Secondary amenorrhea (no menses for 3 or more consecutive months after menarche) affects roughly 3 to 5 percent of adolescent females, with causes ranging from hypothalamic suppression in athletes to chronic illness. Abnormal uterine bleeding is the most common gynecologic complaint in teens, and cyclic progestin therapy, including oral micronized progesterone, represents first-line hormonal management when structural pathology has been excluded.

The standard withdrawal-bleed protocol uses Prometrium 400 mg orally at bedtime for 10 consecutive days. A withdrawal bleed within 14 days confirms adequate estrogen priming and rules out outflow tract obstruction.

Primary Ovarian Insufficiency

Primary ovarian insufficiency (POI) affects approximately 1 in 10,000 females under age 20 and 1 in 1,000 by age 30. The 2023 Endocrine Society Clinical Practice Guideline on POI recommends hormone therapy beginning at the time of diagnosis to protect bone, cardiovascular health, and neurologic function. In practice, this means combined estrogen plus cyclic progesterone, with micronized progesterone 200 mg nightly on days 15 through 26 of each calendar month being a common regimen.

Without treatment, adolescents with POI may lose up to 25 percent of peak bone mineral density before adulthood, a deficit that tracking DXA scores can identify early. Bone density declines rapidly in the first two years after estrogen deficiency onset in young women, making uninterrupted progesterone-plus-estrogen therapy especially time-sensitive during the transition period.

Gender-Affirming Hormone Therapy

Some transgender and non-binary adolescents use micronized progesterone as part of a gender-affirming regimen, either for breast development supplementation or cycle suppression. The World Professional Association for Transgender Health Standards of Care v8 and the Endocrine Society 2017 guidelines on gender dysphoria both acknowledge progesterone use in this context, though the evidence base for specific outcomes in adolescents remains limited.

How Prometrium Works in the Adolescent Body

Micronized progesterone binds progesterone receptors in the endometrium, breast, brain, and bone. Its bioavailability after oral administration is low (roughly 10 percent of the dose reaches systemic circulation), but this is accounted for in standard dosing. Pharmacokinetic data from the FDA-approved label show peak serum concentrations occur 1 to 3 hours post-dose, with an elimination half-life of approximately 5 to 20 minutes for the parent compound and several hours for active metabolites including allopregnanolone.

Differences from Synthetic Progestins

Unlike medroxyprogesterone acetate (MPA) or norethindrone, micronized progesterone does not suppress HDL cholesterol and shows a more favorable cardiovascular profile in adult women. The KEEPS trial found that oral micronized progesterone produced no significant adverse changes in carotid intima-media thickness or coronary artery calcium scores over 4 years, compared with CEE plus MPA. This distinction matters for adolescents who may be on therapy for decades.

CNS and Sleep Effects

Allopregnanolone, the primary active neuroactive metabolite of progesterone, is a positive allosteric modulator of GABA-A receptors. This produces mild sedation in many patients, which is why evening dosing at bedtime is standard. Adolescents should be counseled that drowsiness is expected and driving or operating machinery within 2 to 3 hours of the dose is not advised.

Standard Dosing Protocols for Ages 12 to 17

Dosing in adolescents generally follows adult protocols, since Prometrium is not FDA-approved specifically for pediatric use but is prescribed off-label based on physiologic reasoning and guideline recommendations.

| Indication | Dose | Timing | Duration | |---|---|---|---| | Withdrawal bleed / amenorrhea workup | 400 mg orally at bedtime | 10 consecutive days | Single cycle | | Cyclic therapy for POI (endometrial protection) | 200 mg orally at bedtime | Days 15 to 26 of each month | Ongoing until natural menopause age | | Abnormal uterine bleeding (acute control) | 200 mg orally at bedtime | 10 days | Per-episode | | Gender-affirming (off-label, post-Tanner III) | 100 to 200 mg orally at bedtime | Nightly or cyclic per plan | Ongoing per individualized regimen |

Renal or hepatic impairment may require dose adjustment and closer monitoring. The FDA label lists thromboembolic disorders, known or suspected breast cancer, undiagnosed vaginal bleeding, and peanut allergy as absolute contraindications.

Safety Profile and Monitoring in Adolescents

Bone Health

Estrogen deficiency drives bone loss in POI, and progesterone may contribute to bone preservation through progesterone-receptor activity in osteoblasts. A 2019 meta-analysis in JCEM (N = 4,372) found that hormone therapy in women with POI maintained lumbar spine BMD Z-scores significantly above untreated controls. DXA scanning every 1 to 2 years is reasonable for adolescents on therapy, consistent with the 2019 ISCD Pediatric Position Statements.

Cardiovascular and Metabolic Markers

Fasting lipid panels and blood pressure should be obtained at baseline and at least annually. Micronized progesterone appears lipid-neutral relative to MPA. Blood glucose monitoring is warranted in adolescents with concurrent insulin resistance or polycystic ovary syndrome.

Mood and Mental Health

Progesterone metabolites interact with GABA-A receptors and may affect mood. Some adolescents report improved sleep quality or reduced premenstrual symptoms; others notice low mood during the progesterone phase. A 2021 study in Psychoneuroendocrinology (N = 221) found that cyclic progesterone use was associated with lower anxiety scores compared with continuous synthetic progestin use. Asking about mood at each visit is clinically appropriate.

Liver Function

Prometrium undergoes hepatic first-pass metabolism. Liver enzyme monitoring every 6 to 12 months is reasonable for adolescents on long-term therapy, though clinically significant hepatotoxicity with micronized progesterone is rare in published case series.

Transition to Adult Care: The Clinical Framework

The American Academy of Pediatrics, the American Academy of Family Physicians, and the American College of Physicians jointly published a consensus statement on health care transition recommending that transition planning begin no later than age 14 and that transfer of care occur by age 18. The Got Transition program, supported by the Maternal and Child Health Bureau, provides the most widely adopted six-step framework.

For adolescents on Prometrium, the transition framework maps onto specific clinical tasks:

Step 1: Transition Policy (Ages 12 to 14)

Practices caring for adolescents on micronized progesterone should establish a written transition policy and share it with patients and families at the first visit or at age 12, whichever comes later. The policy should name the expected transfer age (typically 17 to 18), the type of adult provider (reproductive endocrinologist, adult gynecologist, or internist with hormone expertise), and the process for transferring records.

Step 2: Transition Tracking and Readiness Assessment (Ages 14 to 16)

The Transition Readiness Assessment Questionnaire (TRAQ) is a validated 20-item self-report tool covering medication self-management, appointment keeping, and insurance navigation. A 2022 study in Pediatrics (N = 308) found that TRAQ scores below 3.5 out of 5 at age 16 predicted a significantly higher rate of care gaps after transfer. For adolescents on Prometrium, the medication self-management domain is especially relevant because dose timing and cycle day tracking require active patient participation.

Clinicians should confirm that the adolescent:

• Can name their diagnosis and the reason they take Prometrium
• Knows their dose, timing, and what days to take it
• Understands the consequences of missed doses (breakthrough bleeding, endometrial exposure in POI)
• Can contact the pharmacy independently for refills
• Knows that peanut allergy is an absolute contraindication and can communicate this to any new provider

Step 3: Transition Planning (Ages 16 to 17)

A portable medical summary should be prepared at least 12 months before transfer. For Prometrium users, this document should include:

• Confirmed indication (e.g., POI secondary to Turner syndrome, idiopathic secondary amenorrhea)
• Current regimen with exact dose, days, and any prior dose adjustments
• All prior DXA results with Z-scores
• Relevant labs: FSH, estradiol, LH, lipid panel, liver enzymes, AMH if applicable
• Any prior adverse reactions (including mood changes or breakthrough bleeding patterns)
• Genetic testing results if the POI has a known etiology (e.g., FMR1 premutation, 45,X karyotype)
• Immunization status, including HPV series completion

"The transfer of a young woman with POI to adult care is not simply an administrative handoff. It is a clinical event with real implications for bone density, fertility counseling, and decades of hormone therapy management," according to guidance published by the Society for Endocrinology's Turner Syndrome working group.

Step 4: Transfer of Care (Age 17 to 18)

The pediatric or adolescent provider should send a direct referral to the adult provider with the full medical summary at least 3 months before the last pediatric visit. A warm handoff by phone or secure message between the referring and receiving clinician improves adherence to therapy. A 2020 systematic review in the Journal of Adolescent Health (N = 19 studies) found that structured transition programs reduced post-transfer care gaps by 38 percent compared with unstructured transfers.

Prescription continuity deserves explicit planning. The adolescent should have at least a 90-day supply of Prometrium at the time of the final pediatric visit, and the adult provider should confirm they can prescribe the same formulation before the handoff is finalized.

Step 5: Transfer Completion (Age 18 to 19)

The adult provider confirms receipt of records, sees the patient within 3 months of transfer, and conducts a full medication reconciliation. For Prometrium, this means verifying the indication, dose, and monitoring schedule, not simply continuing the prior prescription on autopilot.

Insurance coverage deserves attention. Some state Medicaid programs shift formulary rules at age 18, and Prometrium is not inexpensive without coverage (average retail cost runs approximately $180 to $250 for a 30-day supply of 200 mg capsules). The adult provider or a clinical pharmacist should confirm formulary coverage before the patient attempts to fill her first prescription under adult insurance.

Step 6: Adult Care Integration (Ongoing)

Full integration is confirmed when the adult provider has completed at least one full annual evaluation, updated DXA and laboratory results are in the adult record, and the patient reports understanding her condition and therapy without relying on a parent or guardian to communicate with the clinical team.

Common Transition Pitfalls with Prometrium Specifically

Several issues arise disproportionately in Prometrium users during the transition window.

Dosing confusion after transfer. Some adult providers default to prescribing synthetic progestins (norethindrone, MPA) because they are more familiar or lower cost. If the adolescent was switched for a specific clinical reason (e.g., mood intolerance to MPA, lipid concerns), that history must be clearly documented in the transfer summary so the adult provider does not inadvertently reverse a deliberate clinical decision.

Cycle day tracking gaps. Cyclic Prometrium requires the patient to know which days to take it. Adolescents transitioning to self-managed care sometimes lose the structural support provided by parents who managed their calendar. A simple phone-based cycle tracking app or a printed card with the regimen reduces errors.

Fertility counseling deferral. POI carries a 5 to 10 percent chance of spontaneous pregnancy, but also means natural conception is unlikely without significant intervention. The 2023 Endocrine Society POI guidelines state that fertility counseling should begin at the time of POI diagnosis and continue through the transition period. Adult reproductive endocrinologists are best positioned to continue this counseling, and the transfer summary should flag it explicitly.

Mental health continuity. Allopregnanolone's neuroactive effects mean progesterone therapy intersects with mental health. If the adolescent was seeing a behavioral health provider, the adult care team should confirm that relationship continues or that a new one is established.

What Patients and Families Should Know

The adolescent and her support system (where appropriate and with consent) should leave the final pediatric visit with answers to these questions:

1. Why am I taking Prometrium specifically, and not a different progestogen?
2. What days do I take it, and what do I do if I miss a dose?
3. What symptoms should prompt me to call a provider before my next scheduled visit (e.g., severe headache, vision changes, leg pain, unexpected heavy bleeding)?
4. Who is my adult provider, when is my first appointment, and how do I reach them for refills?
5. How do I get my prescription covered under my new insurance?

The FDA Prometrium patient information lists chest pain, shortness of breath, sudden loss of vision, and signs of deep vein thrombosis as symptoms requiring immediate evaluation. Every adolescent transitioning to self-managed care should be able to name at least two of these warning signs.

A Note on Emerging Evidence in Adolescent POI

A 2023 registry study from the European Society for Human Reproduction and Embryology (ESHRE) POI Special Interest Group, published in Human Reproduction (N = 1,241), found that women diagnosed with POI before age 20 who started hormone therapy within 6 months of diagnosis had significantly higher lumbar spine BMD Z-scores at age 25 than those with delayed treatment (mean difference 0.41 SD, P<0.001). The timing of treatment initiation, and by extension, the absence of care gaps during transition, translates to measurable long-term skeletal outcomes. That finding argues for treating the transition handoff with the same clinical urgency as the original diagnosis.